Form Type: 4

SEC EDGAR Link
Accession Number:0001144204-19-034763
Date:2019-07-11
Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
Original Submission Date:

Reporting Person:

FROM STEPHEN
C/O EYEGATE PHARMACEUTICALS, INC.
271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-07-11 S 42,451 d $0.24 1,117,369 direct
COMMON STOCK 2019-07-12 S 42,452 d $0.24 1,074,917 direct
COMMON STOCK 2019-07-15 S 42,452 d $0.23 1,032,465 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 sale of shares to cover taxes due on restricted stock that vested on 07/10/2019.
f2 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $0.24 to $0.245, inclusive. the reporting person hereby undertakes to provide to eyegate pharmaceuticals, inc., any security holder of eyegate pharmaceuticals, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this form 4.
f3 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $0.2257 to $0.24, inclusive. the reporting person hereby undertakes to provide to eyegate pharmaceuticals, inc., any security holder of eyegate pharmaceuticals, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this form 4.
f4 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $0.227 to $0.2403, inclusive. the reporting person hereby undertakes to provide to eyegate pharmaceuticals, inc., any security holder of eyegate pharmaceuticals, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this form 4.
WhaleWisdom Logo

Elevate your investments